MedTrace Logo

A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

NCT04861779 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2022-08-03

No results posted yet for this study

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of HSK29116 in patients with advanced B-cell malignancies.

Conditions

  • Relapsed/Refractory B-Cell Malignancies

Interventions

DRUG

HSK29116

Oral HSK29116

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Shufang Zhang · Haisco Pharmaceutical Group Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-24
Primary Completion
2023-08-31
Completion
2023-10-31

Countries

  • Australia
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04861779 on ClinicalTrials.gov